Mycofenolaat Mofetil Sandoz (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mycofenolaat Mofetil Sandoz, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is used to prevent organ transplant rejection and to treat lupus nephritis in appropriate patients.

GNH USA supplies Mycofenolaat Mofetil Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Mycophenolate Mofetil is employed in several immunologically mediated conditions, primarily to inhibit lymphocyte proliferation and reduce graft rejection. - Kidney transplant rejection: helps maintain graft function by suppressing immune response. - Heart transplant rejection: reduces the risk of acute and chronic rejection episodes. - Liver transplant rejection: supports long‑term graft survival through immunosuppression. - Lupus nephritis: mitigates renal inflammation and proteinuria in patients with systemic lupus erythematosus.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may affect hydration. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Tremor: mild shaking of hands or limbs. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Opportunistic infections: increased susceptibility to viral, bacterial, or fungal pathogens. - Severe leukopenia: marked reduction in white blood cells. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain disease. - Malignancy: heightened risk of certain cancers with long‑term use. - Severe anemia: significant drop in red blood cell count.

Patients receiving Mycofenolaat Mofetil should be monitored closely for safety and efficacy. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Assess renal function: periodic serum creatinine and eGFR measurements. - Avoid use in pregnancy: drug is classified as Category D due to fetal risk. - Screen for infections: evaluate for latent viral infections before initiation. - Adjust dose in hepatic impairment: consider reduced exposure in liver disease. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several concomitant medications, requiring careful management.

Major Interactions (Avoid): - Azathioprine: additive bone‑marrow suppression. - Live vaccines: increased risk of vaccine‑derived infection. - Cholesterol‑binding resins (e.g., cholestyramine): may reduce drug absorption. - Ribavirin: heightened hematologic toxicity. - High‑dose acyclovir: potential for renal toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., azole antifungals): may increase mycophenolate levels. - NSAIDs: can exacerbate renal impairment. - ACE inhibitors or ARBs: monitor for additive effects on kidney function. - Warfarin: possible alteration of anticoagulant effect. - Diuretics: watch for electrolyte disturbances.